Prime Minister Dmitry Medvedev approved a list of vital and most important medicines for medical applications (ZHHVLP) for 2018. The appropriate disposal prepared by the Ministry of Health was published on the website of the government on October 23.
At the disposal of the Government No. 2323 p of 23.10.17, the lists of the ZHHVLP, drugs appointed to solve the medical commission, LS from the program "7 nosologies", as well as the list of the minimum range of drugs were approved.
Summary table of new MNN included in the list of ZHHVLP for 2018
| MNN | Dosage form |
| Preparations for the treatment of liver disease and biliary tract | |
| Amber Acid + Meglumin + Inosine + Methionine + Nicotinamide | p / r for infusion |
| Anti-inflammable, intestinal anti-inflammatory and antimicrobial drugs | |
| Mesalazin | Suppositories, suspension, pills |
| Tools for treating diabetes | |
| Lixisianatid | |
| Empagliflozin | pills |
| Other preparations for the treatment of diseases of the gastrointestinal tract and metabolic disorders | |
| Eliglustat. | Capsules |
| Hemostatics | |
| Elrombopag | pills |
| Preparations affecting the Renin-angiotensin system | |
| Valsartan + Sakubitril | pills |
| Liberal drugs | |
| Alirocumab | P / P for subcutaneous administration |
| Evavokumab | P / P for subcutaneous administration |
| Hormones of pituitary gland and hypothalamus and their analogues | |
| Lanreotide | Gel for subcutaneous administration of Prolong. actions |
| Antibacterial drugs for system use | |
| Televancin | |
| Daptomycin | lyophilisate for the preparation of P / R for infusion |
| Tetzolid | Tablets, lyophilisate for the preparation of concentrate for the preparation of P / R for infusion |
| Antiviral preparations for systemic use | |
| Dasabuvir; ombitasvir + parityrevir + ritonavir | Tablets set |
| Narlaprevir | pills |
| Daclatasvir | pills |
| Doltegravir | pills |
| Antitumor drugs | |
| Kabasitaxel | |
| Brentuximab Vedin | |
| Nivolumab | Concentrate for the preparation of P / R for infusion |
| Oyanutuzumab | Concentrate for the preparation of P / R for infusion |
| PANITUMUMAB | Concentrate for the preparation of P / R for infusion |
| PEMBROLIZUMAB | Concentrate for the preparation of P / R for infusion |
| Pertuzumab | Concentrate for the preparation of P / R for infusion |
| Trastzumab Emzanzin | lyophilisate for the preparation of concentrate for the preparation of P / R for infusion |
| AFATINIBER | pills |
| Dabrafenib | Capsules |
| Kriziotinib | Capsules |
| Nintedanib | Soft capsules |
| Pasopanib | pills |
| REGRAPENIB | pills |
| Ruxolitinib | pills |
| Tramotinib | pills |
| Aflybercet | Concentrate for the preparation of P / R for infusion |
| Vichelodegib | Capsules |
| CARFILZOMIB | lyophilisate for the preparation of P / R for infusion |
| Alpha-1 tumor necrosis factor [thymbosin recombinant] * | |
| Antitumor hormonal drugs | |
| ENZALAMID | Capsules |
| Degalelix | lyophilisate for the preparation of P / R for subcutaneous administration |
| Immunomodulators | |
| Paginterferon beta-1a | P / P for subcutaneous administration |
| Immununopressants | |
| Aletzumab | Concentrate for the preparation of P / R for infusion |
| APREMILAST | pills |
| Volyasumab | lyophilisate for the preparation of concentrate for the preparation of P / R for infusion |
| Tofacitinib | pills |
| Kanakinumab | lyophilisate for the preparation of P / R for subcutaneous administration |
| Seckinumab | lyophilisate for the preparation of a solution for subcutaneous administration; Solution for subcutaneous administration |
| Pinfenidon | Capsules |
| Anti-inflammatory and anthevatic drugs | |
| Decquetoprofen. | P / R for intravenous and intramuscular administration |
| Levobupivakain | injection |
| Permpanel | pills |
| Dimethylfumarat | Intestinal capsules |
| Tetrabenazine | pills |
| Preparations for the treatment of obstructive respiratory diseases | |
| Vilanterol + Flitazone Furoate | Inhalation Powder Dosage |
| Glixoprony Bromide + Indacterol | Powder capsules for inhalation |
| Olodaterol + Tiotropia Bromide | Inhalation Solution Dosage |
| Other preparations for the treatment of diseases of the respiratory system | |
| Beractant | Suspension for endotracheal administration |
| Preparations for the treatment of eye diseases | |
| Taphluprost | Eye drops |
| Aflybercet | Solution for intraocular injection |
| Other medicaments | |
| Complex B-iron (III) oxyhydroxide, sucrose and starch | Chewing tablets |
| Yomeprol. | injection |
Materials about ZhVLP and other listings:
|
Initially, in terms of combating smoking, a section on the provision of medical care for smokers wishing to get rid of a detrimental habit. In particular, one of the items of such a section was the introduction of drugs for therapy and the cancellation syndrome, in the list of ZHHVLP ... |
According to the Ministry of Economic Development on the re-registration of drugs under the new rules, 140 billion rubles may be required. A negative feedback on the bill was published in early February on the portal of projects of regulatory acts ... |
According to the established procedure, the lists of the ZHHVLP must be published annually, but at the same time changes are made not every year. Last year there were no, and this was introduced to this, which already attracts special attention to the news ... |
Details created: 09.01.2017
Head of the Government of the Russian Federation Dmitry Medvedev signed a decree No. 2885-r about approval of the list of vital and most important drugs (ZHHVLP) for medical applications for 2017. The new list of ZHHVLP is similar to the list of such drugs for 2016.
D.Medvedev: I signed an order of the government, who approves a list of vital and most important drugs for the next, 2017. This is a voluminous document.
The government annually approves such a list. It is aimed at monitoring prices for drugs from this list so that there is no whole kind of speculation and, most importantly, that these medicines remain available to all who acquire them.
Recently, the list began to form more openly, with the direct participation of the professional community. I hope this will allow you to better understand what medications are really in demand, which is happening with pricing, as far as the regions are provided with a particular drug. Prices for drugs and health problems, according to sociological surveys, remain one of the most significant topics for any Russian family. Olga Yurievna (referring to O. Golodets), a few more words about this list tell me, please.
O. Golodets: Indeed, over the past two years, a list of vital and most important drugs was seriously expanded, 96 new names were included in it. In total, it contains 646 international non-proprietary items, and it fully guarantees the provision of medicinal care.
D.Medvedev: International non-proprietary names are, in fact, the chemical formula, and the names of drugs can be different, because they are produced by different suppliers, sometimes with some additives. In short, drugs are more than chemical items.
O. Golodets: Since 2014, a new procedure has been established for the formation of a list of these drugs, which ensures maximum openness and involvement of the expert community. In the work of the Commission, which operates under the Ministry of Health, 46 expert institutions participate. This provides objective and scientific accuracy of the decisions made.
An important trend of recent years is an increase in the proportion of domestic drugs in the LVLP list. As a result of the growth of the Russian pharmaceutical industry and the implementation of the import substitution program, the proportion of domestic drugs was only over the past year from 72% in 2015 to 76.8% in 2016.
In addition to the fact that we are now registering domestic drugs that already exist in the market, we included several innovative drugs that are not in the world market, and their manufacturers are domestic companies. This is a serious step in the development of domestic pharmaceutical.
Next year, at the request of the pharmaceutical manufacturers, the LVLP list will be approved more than once a year, as is happening now, but as new drugs appear. We expect to enter the market for serious drugs that will help in the struggle and with oncological diseases, and with some orphan diseases. They are currently undergoing clinical trials and are already in a high degree of readiness. I hope that those mechanisms that are laid will significantly increase the access of drugs in the Russian market.
D.Medvedev: The fact that changes to the list of JNVLP will be approved more often, really in favor of the work, because when some drug appears, well, if it immediately falls there and becomes available for citizens. We will act in this way.
The list of vital and most important drugs for medical applications for 2017 (approved. Order of the Government of the Russian Federation of December 28, 2016 N 2885-P)
- Back
- Forward
Preferential medicinal provision. Documentation
Order of the Government of the Russian Federation of 12.10.2019 N 2406-P
Register of regional beneficiaries living in the Crimea Resourck. (Order of the Ministry of Health of Kazakhstan No. 1289 of 19.08.2015)
Classifier of individual categories of citizens eligible for drugs on preferential terms. Appendix No. 1 to the order of the Ministry of Health of the Republic of Kazakhstan dated 03.11.2015 №1777
Order of the Ministry of Health of the Republic of Crimea dated June 26, 2016 No. 770 "On Approval of the List of Pharmacies and Pharmacy Points of GUP RK" Crimea Pharmacy "on vacation of preferential drugs, preparations of high-cost nosologies, insulin containing drugs"
Resolution, see RK №38 dated 07/07/15. "On the procedure for implementing in the territory of the Republic of Crimea of \u200b\u200borganizational measures to ensure persons with drugs, intended for the treatment of patients with malignant neoplasms of lymphoid, hematopoiet and related tissues, hemophilia, cystic fibrosis, pituitary tissue, gosh disease, multiple sclerosis, and after organ transplantation and ( or) fabrics "
Order of the Government of the Russian Federation of October 23, 2017. N 2323-R On approval of the list of vital and most important drugs for 2018, a list of drugs for medical use, a list of drugs intended for providing persons with hemophilia patients, cystic rifle, pituitary Gosh's disease, malignant neoplasms of lymphoid, hematopoiet and related tissues, multiple sclerosis, as well as persons after transplantation of organs and (or) tissues, as well as the minimum range of drugs needed to provide medical care (expired)
- Appendix N 1. List of vital and most important medicines for medical applications for 2018
Appendix N 2. List of drugs for medical use, including drugs for medical applications appointed by solving medical commissions of medical organizations Appendix N 3. A list of drugs intended to provide persons with hemophilia patients, cystic cysticity, pituitary nanice, gosh disease, malignant neoplasms of lymphoid, hematopoietic and tissue-related tissues, multiple sclerosis, as well as persons after transplantation of organs and (or) tissues Annex N 4. Minimum range of drugs required to provide medical care
1. Approve:
the list of vital and most important drugs for medical applications for 2018 according to appendix N 1. ;
the list of drugs for medical use, including drugs for medical applications appointed by solving medical commissions of medical organizations, according to appendix N 2. ;
a list of drugs intended for providing persons patients with hemophilia, cystic fibrosis, pituitary nanice, Gosh disease, malignant neoplasms of lymphoid, hematopoietic and tissues, sclerosis, as well as persons after transplantation of organs and (or) tissues, according to appendix N 3. ;
the minimum range of drugs required to provide medical care, according to appendix N 4..
2. Recognize invalid order Government of the Russian Federation of December 26, 2015 N 2724-P (meeting of the legislation of the Russian Federation, 2016, N 2, Art. 413).
The list of vital and most important drugs (ZHHVLP) for medical application for 2018 compared with the LVLP list for 2017 is supplemented by new drugs and dosage forms.
Also approved a new list of drugs to ensure preferential categories of citizens, a list of expensive drugs under the program "7 nosologies" ("Orphans" drugs to provide persons patients with hemophilia, fibrosis, pituitary nanice, Gosh disease, malignant neoplasms of lymphoid, hematopoietic and related neoplasms Fabrics, sclerosis, as well as persons after transplantation of organs and (or) tissues.
The LIST OF ZHHVLP for 2017 approved by the order of the Government of the Russian Federation No. 2885-p dated December 28, 2016 and signed by the head of the government D.A. Medvedev
The LIST OF ZHHVLP for 2017 approved by the order of the Government of the Russian Federation No. 2885-p dated December 28, 2016 and signed by the head of the government D.A. Medvedev.
This list was not expanded, as assumed, and contains 646 items of drugs, which corresponds to about 30 thousand drugs of different dosage forms.
↯ More articles in the magazine
List of JNVLP 2017
The new version of ZHHVLP contains about 30 thousand drugs or 646 international non-proprietary drug names.
Many patients and the medical community as a whole hoped for a significant expansion of the List, however, this issue was postponed by the government until the end of 2017.
Earlier, the Commission of the Ministry of Health of the Russian Federation approved the inclusion of the list of drugs for 2017 by some medicines for the treatment of many severe diseases, including acute heart failure, sclerosis and cancer.
Ignoring the initiative of the Ministry of Health The government explains the severe macroeconomic situation in the Russian Federation and the lack of budget financing.
At the same time, Veronica Skvortsova, Minister of Health of the Russian Federation, believes that the LVLP list for 2017 is sufficient. It is noted that in the period from 2015 to 2016, the list was supplemented with a large number of vital drugs that accounted for 96 positions (they will be discussed below).
Waiting for the critics of the medical community, the Government of the Russian Federation stated that now the LIST of the JNVLP will be complemented by new drugs not annually, but as new drugs are registered.
It should be noted that about 6 subjects of the Russian Federation for preferential groups of patients only from the LVLP list.
Compared to 2016, the decree of the Government of the Russian Federation No. 2885-p was left unchanged by the following drugs:
- preparations for the treatment of patients under the programs "7 nosologies";
- preparations that patients are appointed by solving medical groups of medical institutions;
- preparations that are included in the minimum pharmacy assortment required for medical assistance.
The increase in the number of Russian drugs in ZHHVLP
The trend continues to increase the share of domestic production preparations in the list of vital, which is due to the creation of new, innovative drugs.
In 2016, the proportion of Russian drugs in the list was 76.8% (compared with 2015 - 72%). We believe that in the future this trend will also be marked.
New drugs of domestic production will be included in the list of clinical trials and their state registration. Supplement will occur on the recommendations of the Government of the Russian Federation.
At the same time, a particular attention is paid to the fact that it is not only about generics of well-known, but also on innovative products that are not currently represented at the global pharmaceutical market. This is evidenced by the Deputy Prime Minister on Social Affairs Olga Golodets.
Regional procurement control ZhVLP 2017
In January 2017, a new project of the Independent Monitoring Foundation "Health" was announced. Public scientists within the framework of this project, together with representatives of the All-Russian Popular Front, are planning to introduce a system for controlling the procurement of drugs from a preferential list in the subjects of the Russian Federation.
Participants in the Health Foundation lead the results of independent monitoring, according to which in 79 Russian regions of the lists of preferential drugs are not aligned with the LVLP list.
The situation is stable only in 6 regions - Moscow, Khabarovsk Territory, Orlovskaya, Kursk and Rostov regions, as well as in the Republic of Mari El.
In other regions, statistics are disappointing. For example, in the Kirov region, more than 36% of preferential drugs were not included in the LIST of JNVLP 2017. Maximum numbers are marked in the Altai Territory (more than 41%) and in the Republic of Dagestan (more than 43%).
The current situation leads to a huge financial losses in the procurement of drugs, which in separate regions are up to 30%.
About changing the list of ZHHVLP in 2016
The last large changes in the LVLP list have occurred in 2016 and were approved by the order of the Government of the Russian Federation No. 2724-p dated December 26, 2015.
Next, we consider new drugs in the list. It should be noted that only other dosage forms are added for some drugs, for example, for Pramipexole - a prolonged action tablets. The total number of new positions in the list is 45.
|
No. p / p |
Medicinal preparations (MNN) | Anatomy-therapeutic-chemical classification (ATC) | Dosage form |
|
Preparations for the treatment of diabetes |
|||
| 1 | Insulin Degludek Insulin Aspart | Insulines of the average duration of action or long-acting and their counterparts in combination with short-acting insuls for injection injection | |
| 2 | Insulin Degludek | Long-term insulins and their analogues for injection | Solution for subcutaneous administration |
| 3 | Linagliptin | Dipeptidylpeptidase-4 inhibitors (DPP-4) | |
| 4 | Dapaglifloosin | Other hypoglycemic drugs, except insulins | Tablets covered with film shell |
|
Other preparations for the treatment of diseases of the gastrointestinal tract and metabolic disorders |
|||
| 5 | Laronidase Aldurazim | Enzyme preparations | Concentrate for the preparation of the solution for infusion |
| 6 | Sapropterin | Other drugs for the treatment of diseases of the gastrointestinal tract and metabolic disorders | Dispersible pills |
|
Preparations for the treatment of blood diseases and blood formation systems |
|||
| 7 | Tikagrellor | Antiagregants except heparin | Tablets covered with film shell |
| 8 | Apiksabah | Direct Factor Inhibitors XA | Tablets covered with film shell |
| 9 | Alpha | Blood coagulation factors | |
| 10 | Blood coagulation factors II, VII, IX, X B. Combinations [PromromBin Complex] | Blood coagulation factors | Lyophilisate for the preparation of a solution for intravenous administration |
| 11 | Fibrinogen thrombin | Local hemostatics | Sponge of hemostator |
| 12 | Iron Carboxyimaltozat. | Antianamemic drugs. Parenteral preparations of trivalent iron | |
|
Dermatological preparations |
|||
| 13 | Epidermal growth factor | Other drugs contributing to normal scarring | Lyophilisate for the preparation of the injection solution |
|
Hormonal preparations of system action, except for sex hormones and insulins |
|||
| 14 | Terlimipressin | Vasopressin and its analogues | Solution for intravenous administration |
| 15 | Pacireotide | Somatostatin and analogs | Solution for subcutaneous administration |
|
Antibacterial systemic drugs |
|||
| 16 | Tigecyclin | Tetracyclines | Lyophilisate for cooking for infusion |
|
Antiviral drugs |
|||
| 17 | Lopinavir Ritonavir | A solution for intake; Tablets covered with film shell | |
| 18 | SimePrevir | HIV protease inhibitor | Capsules |
| 19 | RILPIVINE TENOFOVIR EMTICITAINS | Combined antiviral drugs for treating HIV infection | Tablets covered with film shell |
|
Anticancer preparations and immunomodulators |
|||
| 20 | Bendamustine | Antineopole preparation, analogue of nitrogeny yprit | Powder for preparing a concentrate for the preparation of a solution for infusions |
| 21 | Perstuzumab Trastuzumab [set] | Antineopole preparation. Monoclonal antibodies | Set: Concentrate for the preparation of a solution for infusion lyophilisate for the preparation of a concentrate for the preparation of a solution for infusions |
| 22 | Vandetanib | Antineopole preparation. Proteinkinase inhibitors | Tablets covered with film shell |
| 23 | Ibrutinib | Capsules | |
| 24 | Eribulation | Other antitumor drugs | Solution for intravenous administration |
| 25 | Bususelin | Analogs of Gonadotropin Rilizing Hormone | Lyophilisate for the preparation of suspension for intramuscular administration of prolonged action |
| 26 | Ayacteron | Other hormone antagonists and related compounds | Pills |
| 27 | Leflunomide | Selective immunosuppressants | Tablets covered with film shell |
| 28 | Teifflumoid | ||
| 29 | Golimumab | Alpha Tumor Necrosis Factor Inhibitors (TNF Alpha) | Solution for subcutaneous administration |
|
Miorolaxanta |
|||
| 30 | Botulinum toxin type, and | Other mining peripherals | |
| 31 | Buprenorphin | Phenylpipes derivatives | Transdermal plaster |
| Preparations affecting the structure and mineralization of bones | |||
| 32 | Denosuumab | Other drugs affecting the structure and mineralization of bones | Solution for subcutaneous administration |
|
Analgesic |
|||
| 33 | Naloxone oxycodon | Natural alkaloids of opium | Tablets of prolonged action covered with film shell |
|
Psychostimulators and nootropic drugs |
|||
| 34 | Polypeptides of the cerebral cortex | Other psychostimulators and nootropic drugs | Lyophilisate for the preparation of a solution for intramuscular administration |
|
Preparations for the treatment of obstructive respiratory diseases |
|||
| 35 | Indakterol. | Selective beta2-adrenomimetics | |
| 36 | Becmenetazone Formoterol | Adrenergic agents in combination with glucocorticoids or other drugs other than anticholinergic agents | Inhalation aerosol dosage |
| 37 | Mometaone Formoterol | ||
| 38 | Glicopronia Bromide | Anticholinergic agents | Powder capsules for inhalation |
| 39 | Omalizumab | Other means of systemic effects for the treatment of obstructive respiratory diseases | Lyophilisate for the preparation of a solution for subcutaneous administration |
|
Other medicinal drugs |
|||
| 40 | Allergen bacteria [tuberculosis recombinant] | Allergens | Solution for intradermal administration |
| 41 | Sugammadex. | Antidoty | Solution for intravenous administration |
| 42 | Deoxyribonucleic acid plasmid [ultra-propheted ring double-chain] | Other medical agents | Lyophilisate for the preparation of a solution for intramuscular administration |
|
Contrast means |
|||
| 43 | Ghaderemetamide | Paramagnetic contrast agents | Solution for intravenous administration |
| 44 | Gadobenic acid | ||
| 45 | Gadetty acid | ||
Skyrim - Dibella's Heart (passage) Chosen Diebell
Quests for permanent effects
Skyrim - Dibella's Heart (passage) Chosen Diebell
Creating spells in Skyrim
Creating spells in Skyrim